case_images: PMC11760283_01
case_images: Clinical images. Lesions on hands (A) before and (B) 2 weeks after subcutaneous immunoglobulin (SCIG) formulations were switched from SCIG 20% Hizentra to 16.5% Cutaquig for the treatment of SCIG-induced eczematous dermatitis. Patient also using ruxolitinib 1.5% cream.
case_images: gr1.jpg
case_images: PMC11760283_01_gr1.jpg
case_images: fig1
case_images: Hizentra to 16.5% Cutaquig, which helped to reduce the extent of his eczematous dermatitis (Fig 1, B). He has been on Cutaquig for 18 months with very mild and intermittent palmar eczematous dermatitis that he treats with ruxolitinib 1.5% cream as needed.
case_images: Skin biopsy specimen. Spongiosis and inflammatory infiltrates were found on histologic analysis. (Hematoxylin-eosin stain; original magnification: x100.)
case_images: gr2.jpg
case_images: PMC11760283_01_gr2.jpg
case_images: fig2
case_images: A). A shave biopsy from right palm revealed acanthosis, spongiosis with vesiculation, parakeratosis, and an inflammatory infiltrate with lymphocytes predominantly compatible with an eczematous process (Fig 2).